Join to view full profile
1 Barnes Jewish Hospital Plz# DivSt. Louis, MO 63110
Phone+1 314-454-8304
Fax+1 314-454-5902
Dr. Abboud is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2017 - 2020
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2014 - 2017
University of Rochester School of Medicine and DentistryClass of 2014
Certifications & Licensure
IL State Medical License 2020 - 2029
MO State Medical License 2015 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Alpha Omega Alpha University of Rochester, 2014
- Inductee Alpha Omega Alpha Honor Medical Society
Publications & Presentations
PubMed
- Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: R...Brian C Shaffer, Monzr M Al Malki, Antonio Martin Jimenez Jimenez, Joseph Stanek, Stephanie Bo-Subait
American Journal of Hematology. 2026-11-01 - Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.Meagan A Jacoby, David H Spencer, Feng Gao, Geoffrey L Uy, Tasha Burton
NEJM Evidence. 2026-09-01 - Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial.Antonio Martin Jimenez Jimenez, Joseph Stanek, Brent R Logan, Erin Leckrone, Heather E Stefanski
Blood Advances. 2026-08-19
Press Mentions
Itacitinib Helps Prevent Graft Versus Host Disease in Stem Cell Transplant RecipientsDecember 10th, 2024
HMN 2024: New Drug Tested to Reduce Side Effect of ‘Half-Matched’ Stem Cell TransplantsDecember 6th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
